Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects a steep drop in sales of its COVID products ...

Pfizer last month closed its up to $10bn (€8.5bn) acquisition of Metsera after winning shareholder approval, gaining a ...

President Trump announced landmark drug pricing agreements with nine pharmaceutical companies and the launch of TrumpRx.gov, ...

The president made a wide variety of claims Wednesday night. Some were true, some were misleading, and others were false.

The talks follow the administration’s push to lower U.S. drug prices using trade and regulatory leverage. ・Pfizer and ...

The U.S. stock market drifted through a mixed day of trading Dec. 16 after reports on the economy did little to clear ...

Morning Brief host Julie Hyman breaks down the biggest market stories developing on December 16, 2025. RSM chief economist ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...